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2.1. Epidemiology of type 2 diabetes mellitus (T2D) 
2.1.1. Prevalence of T2D 
Worldwide, over 400 million people at the age of 20-79 years are estimated to live with 
diabetes mellitus [1, 2]. In industrialized countries, the proportion of patients with type 2 
diabetes mellitus (T2D) is about 90% of all cases of diabetes [2]. T2D therefore causes both a 
great economic and, for the individuals affected, also a personal burden. Globally, the total 
health care expenditure in 2015 due to diabetes in 20-79 year-old patients has been estimated 
to be US $673 billion and is expected to rise to more than US $800 billion in 2040 [2]. The 
personal consequences for patients are a limitation in quality of life, disability [3-5], and 
increased mortality rates [2]. These burdens will increase further with the continuously rising 
prevalence. In 2040, the global prevalence of diabetes is expected to exceed 10% (642 million 
people) [2]. To reverse this trend, prevention must be improved and progression of the 
disease minimized. 
2.1.2. Undiagnosed prediabetes and T2D 
The worldwide proportion of adults with unknown diabetes is estimated to be 46.5% (192.8 
million people) of all cases of diabetes [2]. Even in industrialized countries, screening studies 
show that the rate of unknown diabetes among the general population is high [6, 7]. For 
Europe, the amount of undiagnosed diabetes in adults was found to still be 39.3% (23.5 million 
people) [2]. Almost all cases of unknown diabetes are T2D, because the clinical presentation 
of other forms of diabetes is much clearer.  
Oral glucose tolerance testing (oGTT) is the gold standard method to test for prediabetes and 
T2D. However, it is time consuming and expensive. Therefore, routine screening for T2D is 
usually conducted with fasting glucose and hemoglobin A1c (HbA1c) only [8]. This strategy 
misses subjects with the prediabetic stage of impaired glucose tolerance and also early forms 
of T2D [9, 10]. Diagnostics of prediabetes and early T2D are thus still suboptimal. Similarly, 
risk prediction for T2D is incomplete and rather simple-minded. Current risk scores in principle 
detect the metabolic syndrome, ask for a family history of diabetes, and older age [8, 11]. 
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Consequently, the scores miss individuals without these characteristics, in particular young 
and lean patients, which certainly exist in rather large numbers.  
2.1.3. Consequences of insufficient diagnostic tools 
With the current screening methods, many individuals with prediabetes and early T2D are 
missed. This is problematic, because disease duration is a critical point for the success of 
lifestyle interventions: the longer glucose metabolism has been deranged, the lesser patients 
benefit from intervention programs [12]. Thus, healthy subjects at high risk for T2D and 
subjects in a prediabetic stage should be the key target groups for prevention programs. To 
identify more subjects at high risk, a reliable prediction of T2D through cost-effective 
biomarkers is needed.  
2.2. Heterogeneity of T2D 
Another problem, besides the lack of sufficient prediction and early detection, is that, after 
diagnosis, T2D therapy follows a “one size fits all” approach [8, 11]. This leads to 
heterogeneous responses to therapy, which is not surprising given the diversity of the 
patients’ phenotypes [13-15].  
The general preconception of T2D as a disease of older age and obesity/the metabolic 
syndrome also has to be revisited. The metabolic syndrome is a cluster of changes that 
unquestionably put affected individuals at high risk for cardiovascular diseases and T2D [16]. 
Despite small differences [17-21], all definitions of the metabolic syndrome include the same 
clinical conditions: hyperglycemia, central obesity, hypertension, and dyslipidemia. However, 
the proportion of T2D cases that do not have the classical phenotype is noteworthy. For 
example, almost one third of incident T2D cases in the United Kingdom Prospective Diabetes 
Study cohort was lean with a BMI of less than 25kg/m2  [22, 23].  
Particularly this high proportion of lean T2D patients substantiates the need for research on 
T2D pathophysiology apart from the contribution of obesity. This could enable a better 
prediction of T2D risk in lean subjects, facilitate the development of novel, cost-effective 
biomarkers, and could lead to more tailored intervention programs. Thereby, the onset of T2D 
could be delayed or even prevented. Understanding pathophysiological differences between 
5 
different groups of patients would also permit individualized therapy guidelines. Finally, 




3. The PPSDiab study 
Previous studies on T2D mostly included older subjects with incident or even long-standing 
diabetes [24-27]. This complicates research, as the subjects often have co-morbidities and 
medication affecting metabolism. An optimal study design should therefore be prospective, 
including young and healthy subjects with the development of T2D as primary endpoint.  
Based on these criteria, the Prediction, Prevention and Subclassification of type 2 Diabetes 
(PPSDiab) study was designed. To pre-select for individuals at high risk for T2D, women after 
a pregnancy complicated by gestational diabetes mellitus (GDM) were recruited preferentially 
[28]. GDM serves as a risk-marker for T2D because pregnancy is a stress test for glucose 
metabolism [29]. Nevertheless, GDM is a transient condition, meaning that after delivery 
affected women usually return to normoglycemia [29, 30]. This allows for the inclusion of 
healthy subjects who are at high risk for T2D. Additionally, the inclusion of women after a 
recent pregnancy naturally results in a cohort of young adults.  
The baseline visit of the PPSDiab study was conducted with 304 women 3-16 months after the 
index pregnancy. Women after a pregnancy complicated by GDM were included as cases and 
women after a normoglycemic pregnancy served as controls in a ratio of 2:1. The study has 
yearly follow ups, which include an oGTT, medical and family history, anthropometric 






Figure 1: PPSDiab study design.  
GDM: gestational diabetes mellitus, ivGTT: intravenous glucose tolerance test, MRI: magnetic 
resonance imaging, oGTT: oral glucose tolerance test, T2D: type 2 diabetes mellitus 
All analyses for this thesis were done with data from the baseline visit of the PPSDiab study. 
Detailed information about the baseline characteristics of the PPSDiab study cohort is given 
in a publication by Rottenkolber et al. [31].  
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4. Specific aims of this thesis 
4.1. Physical fitness, leptin, and T2D risk 
Physical activity and fitness are known determinants of T2D risk and other cardiovascular 
diseases [32-34]. One possible reason for the reduction of T2D risk with increased physical 
activity could simply be an increased energy expenditure, counterbalancing excessive energy 
supply and preventing obesity. Furthermore, exercise increases the quantity of the glucose 
transporter GLUT-4 on the plasma membrane of contracting muscle cells, leading to an 
enhanced glucose uptake into the muscle [35, 36]. This positive effect of exercise continues 
even after cessation of activity: A meta-analysis by Way et al. confirmed improved insulin 
sensitivity following the last of at least 3 bouts of exercise [37]. Exercise also alters inter-organ 
communication via myokines (i.e. cytokines produced by skeletal muscle), which can also 
affect glucose metabolism in a positive manner [38]. 
Physical fitness covers cardiorespiratory and muscular endurance, muscular strength, body 
composition, and flexibility [39]. In T2D research, cardiorespiratory fitness (measured as 
maximal oxygen uptake in cardiopulmonary exercise testing) is most commonly used as a 
surrogate parameter also for the other domains of general physical fitness. Sui et al. have 
shown that high cardiorespiratory fitness independently reduces the risk for the development 
of T2D [40]. Besides inherited factors, the amount of regular physical activity is the main 
determinant of physical fitness [40]. Beyond the effects of regular physical activity (see above), 
a high physical fitness improves glycemia as it is positively associated with muscle mass [35, 
36]. A high muscle mass improves postprandial glucose tolerance, because skeletal muscle is 
the main organ for glucose deposition in that situation [41]. 
Physical activity and fitness have been shown to be negatively associated with plasma leptin 
levels in humans [42-47]. The adipokine leptin is secreted by the adipose tissue in positive 
correlation to the amount of stored energy [48, 49]. It mainly acts centrally to control energy 
[48, 49] and glucose homeostasis [50-52]. Both leptin deficient and leptin resistant 
phenotypes are characterized by hyperinsulinemia, insulin resistance, and hyperglycemia [52]. 
Consequently, euglycemia requires adequate leptin action. Leptin resistance can be observed 
in overweight and obese individuals, where central leptin action is insufficient despite high 
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amounts of leptin being produced by adipose tissue [53]. Therefore, leptin resistance is one 
link from overweight/obesity to disturbed glucose homeostasis.  
We examined the association of physical fitness with T2D risk and recent GDM on the one 
hand, and with plasma leptin levels on the other hand. We hypothesized that if physical fitness 
would associate with leptin levels, it might affect leptin resistance. Therefore, increasing 
physical fitness may potentially counterbalance some of the negative effects of obesity in our 
study population. 
4.2. Plasma glucagon and prediabetes 
In the pancreatic islet, alpha-cells secrete glucagon to counteract hypoglycemia [54]. This 
raises plasma glucose by an increase in gluconeogenesis and glycogenolysis and a reduction 
of glycolysis [54, 55]. Insulin serves as a negative feedback for alpha-cells and inhibits the 
secretion of glucagon [54]. Hence, rising insulin levels in an oGTT are expected to suppress the 
release of glucagon. Diminished insulin secretion, as seen in T2D, could therefore lead to 
differences in the glucagon response. High glucagon levels could also add to hyperglycemia 
independent of insulin levels [54]. 
The literature about glucagon levels in T2D is inconsistent. Some studies showed high fasting 
glucagon and insufficient glucagon suppression during an oGTT in prediabetes and T2D  [56-
59] while others found no alterations [60]. 
We examined the plasma glucagon dynamics during an oGTT in different metabolic subgroups 
(normoglycemic, prediabetes, T2D) of the PPSDiab study cohort. 
4.3. Serum and plasma amino acids as risk markers for T2D 
Because routine screening misses many cases of early T2D and especially prediabetes [9, 10], 
novel biomarkers are needed. Amino acids serve as precursors for gluconeogenesis [61] and 
derangements of glucose homeostasis are reflected by amino acid metabolism [62]. 
Therefore, amino acids possibly serve as biomarkers for T2D. However, blood amino acid 
levels are also altered by other factors like nutrition and comorbidities [61]. For example, 
blood amino acid profiles differ between lean and obese subjects [63] and also associate with 
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hypertension, dyslipidemia, and the metabolic syndrome [64, 65]. These data point to the 
question whether amino acids can reliably indicate glycemia besides being affected by many 
other conditions. 
We reviewed the current literature on serum or plasma amino acids as biomarkers for 
prediabetes and T2D and also analyzed original data from the PPSDiab study. Here we 
examined, whether plasma amino acid levels reflect pathological glucose tolerance and other 




5.1. Physical fitness and leptin 
In the PPSDiab study cohort, women post GDM had a lower physical fitness (measured as 
maximum oxygen uptake and maximum load in cardiopulmonary exercise testing) than 
control subjects after a normoglycemic pregnancy. This association remained significant after 
adjustment for BMI, age, and months post-delivery. The results suggest that reduced physical 
fitness is an independent risk factor for the increased T2D-risk in the post GDM group of 
women, and potentially also for the GDM itself. 
Fasting plasma leptin levels associated inversely with physical fitness and the insulin sensitivity 
index, and positively with the BMI in our study. The negative association of leptin with physical 
fitness was confirmed by a linear regression analysis adjusted for BMI or body fat mass. These 
data confirm previous results [42-44, 47] and could mean that physical fitness influences 
insulin sensitivity via leptin signaling (Figure 2). This conclusion needs further examination, 
e.g. in intervention trials aiming at a weight stable improvement of physical fitness. 
Additionally, to address this and similar questions, we recently set up a new protocol for 
cardiopulmonary exercise testing that has a specific focus on glucose metabolism and 
hormonal signaling. 
 
Figure 2: Suggested interrelation of physical fitness, plasma leptin, and glucose homeostasis.  
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5.2. Plasma glucagon 
In our study, mean fasting glucagon levels were higher and glucagon suppression during oGTT 
was delayed in the prediabetes-/T2D-group. These were expected findings. However, the 
plasma glucagon dynamics were not homogeneous within the metabolic groups that we 
examined. Instead, an unsupervised cluster analysis showed 4 patterns of glucagon dynamics 
that did not match the predefined metabolic groups. 
Clusters with high fasting glucagon and delayed glucagon suppression were enriched for 
subjects at high risk for T2D but also contained a large proportion of control subjects. 
Conversely, subjects from high-risk groups were also found in the “healthiest” glucagon 
cluster characterized by low fasting glucagon and appropriate glucagon suppression. We 
conclude that hyperglucagonemia may promote hyperglycemia, but it is neither a clear 
indicator nor a prerequisite for T2D. 
With respect to the metabolic syndrome, the cluster with high fasting glucagon and poor 
glucagon suppression clearly differed from the other clusters. Despite their low mean age, the 
women in this cluster had the highest mean BMI, waist circumference, high-sensitivity c-
reactive protein, liver fat, and intra-abdominal fat, and the worst insulin sensitivity. Hence, 
fasting plus postprandial hyperglucagonemia is closely linked to the metabolic syndrome. 
5.3. Serum and plasma amino acids 
Our systematic literature review revealed several candidates that are most consistently 
associated with pathological glucose metabolism: the branched chain amino acids (isoleucine, 
leucine, and valine), aromatic amino acids (alanine and proline), glycine, and glutamate. Our 
own data from the PPSDiab study showed that isoleucine, leucine, the sum of the branched 
chain amino acids, proline, glycine, and glutamate were significantly associated with 
pathological glucose tolerance. Except for glycine, all associations of amino acids with the 
glycemic state were lost with BMI-adjustment in a logistic regression analysis. 
Furthermore, not only the glycemic state, but also other components of the metabolic 
syndrome (BMI, blood pressure, and lipids) associated with plasma amino acids. Classic risk 
models for the development of T2D already include these factors of the metabolic syndrome. 
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Thus, the addition of plasma amino acids does not substantially improve already established 
clinical models, except possibly for glycine. 
5.4. T2D beyond obesity 
This thesis aimed at the characterization of several factors, other than obesity, that are 
associated with T2D risk in young women. It reveals new aspects of T2D pathophysiology, 
highlights the heterogeneity of this disease, and critically evaluates a class of potential novel 
biomarkers. Together with other recent studies, our results show that there is still a lot to 
learn about T2D and that distinct disease subtypes likely exist but are still underappreciated. 
Future work will hopefully close these gaps in our knowledge and will provide means for 
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S1 Table. Characteristics of the study sample. BIA: bioelectrical impedance analysis; BMI: body 
mass index; ISI: insulin sensitivity index; MRI: magnetic resonance imaging. 







 N 236 63  
 pGDM 152 (64.4%) 45 (71.4%) 0.2963 
Clinical 
parameter  
Age [years] 35.9±4.1 33.7±5.2 0.0021 
Waist circumference 
[cm] 
80.6±11.3 84.1±12.1 0.0373 
BMI [kg/m²] 
(missing=2) 
25.0±5.4 27.2±7.5 0.0352 
Fat mass in BIA 
(missing=5) 
23.1±10.5 27.7±14.9 0.0266 
Total fat mass in 
MRI (missing=135) 
25.5±10.8 28.1±23.8 (n=10) 0.5340 
Systolic blood 
pressure [mmHg]  
117.2±11.4 118.8±12.6 0.3219 
Diastolic blood 
pressure [mmHg]  
73.4±9.1 75.2±10.0 0.1959 
Months post-
delivery 
9.3±2.8 9.6±2.7 0.4821 
Laboratory 
parameter 
Leptin [ng/ml] 10.1 (4.9-15.7) 11.2 (7.3-16.9) 0.0574 
Adiponectin [ng/ml] 11.6 (8.0-14.9) 9.8 (6.4-14.5) 0.0953 










62.0 (55.0-73.0) 62.0 (46.0-69.0) 0.1333 
Triglycerides 
[mg/dl] 





91.0 (87.0-97.0) 94.0 (87.0-100.0) 0.1899 











S2 Table. Linear regression analysis - dependent variable VO2peak/kg (ml/min/kg),  VO2peak or 
Max. load (all logarithmized), independent variable pGDM/control status. BIA: bioelectrical 
impedance analysis; CI: confidence interval; Max. load: maximum workload in cardiopulmonary 
exercise testing; VO2peak: peak oxygen uptake; VO2peak/kg: peak oxygen uptake per body mass. 
 VO2peak/kg 
(ml/min/kg) 
















Adjustment for fat mass in BIA 
 0.11 (0.06-
0.15) 
<0.0001 0.54 0.13 (0.07-
0.18) 
<0.0001 0.08 0.15 (0.09-
0.20) 
<0.0001 0.14 
Adjustment for fat mass in BIA, age, and months post-delivery 
 0.11 (0.06-
0.16) 
<0.0001 0.55 0.13 (0.08-
0.18) 







S3 Table. Linear regression analysis - dependent variable VO2peak/kg (ml/min/kg),  VO2peak or 
Max. load (all logarithmized), independent variable pGDM/control status. Analysis of participants 
with MRI data (n=154). CI: confidence interval; Max. load: maximum workload in cardiopulmonary 
exercise testing; MRI: magnetic resonance imaging; VO2peak: peak oxygen uptake; VO2peak/kg: peak 
oxygen uptake per body mass. 
 VO2peak/kg 
(ml/min/kg) 






















Adjustment for total fat mass in MRI 
 0.08 (0.02-
0.14) 
0.0092 0.56 0.09 (0.03-
0.16) 
0.0045 0.04 0.11 (0.05-
0.17) 
0.0007 0.14 
Adjustment for total fat mass in MRI, age, and months post-delivery 
 0.08 (0.02-
0.14) 
0.0065 0.56 0.10 (0.04-
0.17) 






S4 Table. Linear regression analysis – dependent variable leptin (logarithmized), independent 
variable VO2peak/kg (ml/min/kg), VO2peak or Max. load. BIA: bioelectrical impedance analysis; CI: 
confidence interval; pGDM: previous gestational diabetes; Max. load: maximum workload in 
















































S5 Table. Linear regression analysis – dependent variable leptin (logarithmized), independent 
variable VO2peak/kg (ml/min/kg), VO2peak (logarithmized) or Max. load  (logarithmized). Analysis 
of participants with MRI data (n=154). CI: confidence interval; Max. load: maximum workload in 
cardiopulmonary exercise testing; MRI: magnetic resonance imaging; pGDM: previous gestational 
diabetes; VO2peak: peak oxygen uptake; VO2peak/kg: peak oxygen uptake per body mass. 
 VO2peak/kg 
(ml/min/kg) 
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Supplemental Table 1: Comparison of glucagon values measured with RIA vs. ELISA 
(n=283); RIA: radioimmunoassay, ELISA: Enzyme-linked Immunosorbent 
Assay, GDM-NG: normoglycemic subjects at baseline after a pregnancy complicated by 
gestational diabetes; GDM-PGM: subjects after a pregnancy complicated by 
gestational diabetes with pathological glucose tolerance at baseline 
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Supplemental Fig. 1: Comparison of glucagon curves measured with RIA vs. ELISA 






Supplemental Table 2: Fasting plasma glucagon and glucagon suppression indices during oGTT in different groups of prediabetes (isolated IFG, 




Supplemental Fig. 2: Plasma glucagon during oGTT in different groups of prediabetes 
(isolated IFG: light pink; isolated IGT: red; combined IFG+IGT: brown). 




Supplemental Fig. 3: Glucagon curves stratified by risk group (blue = controls, gray = normoglycemic high-risk, red = prediabetes/diabetes) and 
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Serum and Plasma Amino Acids as Markers of Prediabetes, Insulin Resistance, and 
Incident Diabetes—Systematic Literature Review and Results from a Cohort Study of 
Young Women. 
Gar C.1.2.3., Rottenkolber M.1.2.3., Prehn C.4., Adamski J.4., Seissler J.1.2.3., Lechner A.1.2.3.. 
1Diabetes Research Group, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany 
2Clinical Cooperation Group Type 2 Diabetes, Helmholtz Zentrum München, Neuherberg, Germany 
3Deutsches Zentrum für Diabetesforschung (DZD), Germany 
4Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental 
Health, Neuherberg, Germany 
5Lehrstuhl für Experimentelle Genetik, Technische Universität München, Freising-Weihenstephan, Germany 
 
Corresponding author: Andreas Lechner, MD, Diabetes Research Group, Medizinische Klinik und Poliklinik IV, Ziemssenstrasse 1, 80336 
München, Germany. E-mail: andreas.lechner@med.uni-muenchen.de; Phone: +4989440052185; Fax: +4989440053374 
Online Resource 1: Materials and methods 
Systematic review 
Our search in MEDLINE for previous systematic reviews on the subject produced/yielded a 2015, high-
quality publication by Guasch-Ferre et al. [68]. We used this publication as the starting point for our 
literature search and conducted a qualitative review of observational human studies published 
subsequently that analyzed plasma amino acids and their relationship to prediabetes and T2D. Our 
search strategy mirrored Guasch-Ferre et al. [68] and focused on MEDLINE for publications from 
August 1, 2015 until May 10, 2017, because this period is not covered by Guasch-Ferre et al.  
Search strategy: 
MEDLINE was searched for articles published between 08/01/2015 and 05/10/2016 in English 
using the following search term: 
((“metabolomics”[MeSH Terms] OR “metabolomics”[All Fields] OR “metabolome”[MeSH 
Terms] OR “metabolome”[All Fields]) AND (“diabetes mellitus”[MeSH Terms] OR 
(“diabetes”[All Fields] AND “mellitus”[All Fields]) OR “diabetes mellitus”[All Fields] OR 
“diabetes”[All Fields] OR “type 2 diabetes”[All Fields] OR “metabolic diseases”[MeSH Terms] 
OR “insulin resistance”[All Fields] OR “insulin sensitivity”[ All fields] OR “metabolic 
syndrome x”[MeSH Terms] OR “metabolic syndrome”[All Fields] OR “HOMA-IR”[All Fields] 
OR “HOMA- β”[All Fields] OR “impaired glucose”[All Fields] OR “impaired fasting 
insulin”[All Fields]) AND “humans”[MeSH Terms]) 
All stages of publications (early view, in press, published) in English were considered relevant. Inclusion 
criteria were also adapted from Guasch-Ferre et al. [68] (observational human studies on prediabetes or 
T2D plus the measurement of a plasma or serum amino acid panel; in contrast to Guasch-Ferre et al., 
we did not include studies on urinary amino acids). Study quality was rated following the STROBE 




Flow chart of literature search and selection process. 
  
  
Initial search in PubMed for  
2015/08/01  –   2016/08/31:   
n=164   
excluded n=140   
excluded n=7   
no assessment of direct association of AAs with diabetes n=2   
no measurement of AAs n=2   
genetic studies n=2   
exercise measurement n=1   
excluded n=13   
reviews and other non - observational studies n=9   
no assessment of direct association of AAs with diabetes n=4   
articles included  for  
systematic review   n=4   
full text articles  assessed  
for eligibility n=11   
abstracts  for review n=24   
3 cross - sectional  studies   1 longitudinal study   
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PPSDiab study design and participants  
The observational, prospective cohort study PPSDiab [70] assessed women 3–16 months after delivery 
with either gestational diabetes or normoglycemia during pregnancy at the Medical Center of the 
University of Munich (“Klinikum der Universität München”), Germany, starting in November 2011. 
Recruitment for the sample analyzed here concluded in December 2013. Gestational diabetes mellitus 
was diagnosed with a 75g oral glucose tolerance test (oGTT) and according to the IADPSG criteria [71]. 
Exclusion criteria were alcohol or substance abuse and chronic diseases requiring systemic medication 
(except for hypothyroidism (n=23), mild hypertension (n=1), bronchial asthma (n=3), and seasonal 
allergies treated with desloratadine (n=1)). Four women included in this analysis without a clear medical 
diagnosis were also taking daily medication at the time of the study visit (proton-pump inhibitors (n=3) 
and dehydroepiandrosterone (n=1)). 
Written informed consent was obtained from all study participants, and the study protocol was approved 
by the ethics review committee of the Ludwig-Maximilians-Universität in Munich, Germany. 
Two participants were excluded from the analysis because of a diagnosis of hyperthyroidism (n=1) and 
positivity for GAD65 and IA2 antibodies (n=1) respectively. The final sample included 151 women. 
PPSDiab study procedures 
Participants underwent a five-point, 75g oGTT with measurement of plasma glucose and serum insulin 
(after an overnight fast) and were divided into normoglycemic subjects [NGT; fasting plasma glucose 
5.6 mmol/l (<100 mg/dl) and 2h plasma glucose 7.8 mmol/l (<140 mg/dl)) and subjects with 
pathological glucose tolerance (PGT; fasting plasma glucose ≥5.6 mmol/l (≥100 mg/dl) and/or 2h 
plasma glucose ≥7.8 mmol/l (≥140 mg/dl)]. The oGTT data were also used to calculate the insulin 
sensitivity index according to Matsuda and DeFronzo [72] as well as the homeostasis model assessment 
insulin resistance index (HOMA-IR) [73].  
Metabolite quantification out of fasted plasma samples was conducted using the targeted metabolomics 
assay AbsoluteIDQTM p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria) and liquid 
chromatography-triple quadrupole mass spectrometry (LC-MS/MS). The assay procedures of the 
AbsoluteIDQTM p180 Kit have been described in detail previously [74]. Concentrations of all 
metabolites were calculated using internal standards and reported in μM. Amino acids and related 
biogenic amines, as represented in the kit, were included in this analysis. These were: alanine (ala), 
arginine (arg), asparagine (asn), aspartate (asp), citrulline, glutamine (gln), glutamate (glu), glycine 
(gly), histidine (his), isoleucine (ile), leucine (leu), lysine (lys), methionine (met), ornithine (orn), 
phenylalanine (phe), proline (pro), serine (ser), threonine (thr), tryptophan (trp), tyrosine (tyr), valine 
(val), acetylornithine, asymmetric dimethylarginine, alpha-aminoadipic acid, creatinine, kynurenine, 
putrescine, serotonin, taurine, the sum of the aromatic amino acids (AAAs), and the sum of the branched-
chain amino acids (BCAAs).  
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Anthropometric data and body fat mass, as determined by a bioimpedance measurement, were also 
obtained. A detailed description of the study design, anthropometric and clinical measurements as well 
as methodologies of blood sampling and analysis has been published previously [70]. In brief, fasting 
plasma samples were collected in protease inhibitor containing tubes (P800 vacutainer, BD Biosciences, 
Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA). After blood sampling, plasma 
was immediately processed and subsequently stored at -80°C until analysis. 
Statistical analysis 
All numerical values are presented as mean ± standard deviation (SD) or median (first - third quartile). 
Proportions were compared using chi-squared test or Fisher’s exact test. Different groups were 
compared using a t-test or Mann–Whitney U-test. The Benjamini–Hochberg method was used to correct 
for multiple testing. To assess whether a variable is normally distributed or not, the Shapiro–Wilk test 
was used. Logistic regression models with NGT/PGT status as dependent and plasma concentrations 
and/or BMI as independent variables were performed for selected metabolites. All statistical analyses 
were performed using SAS statistical software package, version 9.3 (SAS Institute Inc., Cary, North 
Carolina, USA) and R version 3.1.3 (R Development Core Team, Vienna, Austria). 
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Online Resource 2 
Study characteristics and main findings for the systematic review  

















































measures (2h glucose, 
HOMA-IR);  
9 studies prediabetes 






oGTT glucose AUC);  
8 studies prediabetes 







association with prediabetes:  
(↑) BCAAs, AAAs, ala, pro, 
gln/glu ratio 
(↓) gly, ser, gln; 
association with T2D:  
(↑) BCAAs, AAAs, ala, glu, lys, 
alpha-/beta-HB 
(↓) gly, his 
Meta-analysis†: 
ile RR=1.36 (1.24–1.48),  
leu RR=1.36 (1.17–1.58),  
val RR=1.35 (1.19–1.53),  
tyr RR=1.36 (1.19–1.55),  
phe RR=1.26 (1.10–1.44),  
gly (RR=0.89 (0.81–0.96),  
gln (RR=0.85 (0.82–0.89),  
ala (RR=1.19 (0.99–1.42),  
his (RR=0.98 (0.91–1.06),  
arg (RR=1.19 (1.14–1.25), orn 
























sex, age, and 
BMI 










* Score calculated as sum of criteria fulfilled/sum of criteria requested.  
†prospective association of amino acids with T2D; pooled RR for incident T2D per study-specific SD difference in the amino acid analyzed; 
 (↑), positive association (e.g., higher metabolite, higher risk); (↓), inverse association (e.g., lower metabolite, lower risk) with prediabetes traits or type 2 diabetes.  
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association with HOMA-IR: 
(↑) ala, alpha-ketoglutarate, 
aminoadipic acid, ile, kynurenine, 
leu, pro, tyr, val 
(↓) asn, gly, SDMA 
association with fasting glucose: 
(↑) alpha-HB, beta-HB, isocitrate 

































age, sex, and 
BMI 
association with HOMA-IR and 
fasting insulin: 
(↑) pro, leu 
association with fasting glucose:  
(↑) creatine, pro 
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Comparison of plasma amino acids in NGT and PGT group (PPSDiab study) 
 Fold change NGT vs. PGT-group p value 
alanine 0.963784208822498 0.449158005020214 
arginine 1.02143595351558 0.830169269640774 
asparagine 0.990206117990152 0.981519806304174 
aspartate 0.937309545274435 0.449158005020214 
citrulline 0.969422343700731 0.981519806304174 
glutamine 1.06320978860949 0.0759106163604412 
glutamate 0.758478365193794 0.0147770300563038 
glycine 1.20764320964134 0.0147770300563038 
histidine 1.00357421130837 0.947178590532944 
isoleucine 0.92254202298691 0.0147770300563038 
leucine 0.938875699691918 0.0355730504363148 
lysine 1.00042060030229 0.981519806304174 
methionine 1.0102707042081 0.853221343178087 
ornithine 1.04449593578243 0.471775515093756 
phenylalanine 0.949272721372389 0.0632558716223262 
proline 0.922549074179386 0.0147770300563038 
serine 1.05164897135846 0.471775515093756 
threonine 1.01159818360666 0.981519806304174 
tryptophane 1.00151202879749 0.981519806304174 
tyrosine 0.964809232223344 0.418921357490307 
valine 0.958299576211642 0.247730477421767 
Ac-Orn 1.19792481428624 0.549542664740572 
ADMA 1.00078011187636 0.982895333686895 
alpha AAA 0.836062916498834 0.0577518126920937 
creatinine 0.995972176258046 0.981519806304174 
kynurenine 0.989914692206711 0.981519806304174 
putrescine 1.05291533711337 0.549542664740572 
serotonine 0.937303630463963 0.549542664740572 
taurine 1.01876587858866 0.853221343178087 
AAAs 0.946260539389602 0.0858961121448052 




Spearman correlation of amino acids and selected biogenic amines with components of the metabolic syndrome (PPSDiab study) 
 correlation coefficient p-value number of participants (n) 
Variable ISI BMI sysBP TG HDL ISI BMI sysBP TG HDL ISI BMI sysBP TG HDL 
alanine -0.2295 0.1292 0.0860 0.1956 -0.1784 0.0049 0.1152 0.2956 0.0161 0.0284 149 150 150 151 151 
arginine 0.1175 -0.1044 -0.0027 -0.1140 0.1016 0.1535 0.2035 0.9742 0.1633 0.2145 149 150 150 151 151 
asparagine 0.1767 -0.2308 -0.2051 -0.1101 0.1550 0.0311 0.0045 0.0118 0.1782 0.0575 149 150 150 151 151 
aspartate -0.1102 0.0618 -0.1151 0.1188 -0.0483 0.1810 0.4525 0.1607 0.1463 0.5557 149 150 150 151 151 
citrulline 0.1872 -0.2155 -0.2232 -0.1881 0.2721 0.0223 0.0081 0.0060 0.0207 0.0007 149 150 150 151 151 
glutamine 0.2127 -0.0946 -0.0507 -0.2198 0.1230 0.0092 0.2497 0.5381 0.0067 0.1325 149 150 150 151 151 
glutamate -0.4853 0.4787 0.1144 0.3392 -0.2941 0.0000 0.0000 0.1635 0.0000 0.0002 149 150 150 151 151 
glycine 0.3680 -0.3436 -0.2792 -0.2212 0.2007 0.0000 0.0000 0.0005 0.0063 0.0135 149 150 150 151 151 
histidine 0.1186 -0.0760 -0.0132 0.0111 -0.0378 0.1498 0.3555 0.8730 0.8920 0.6453 149 150 150 151 151 
isoleucine -0.3294 0.3558 0.2065 0.1862 -0.4107 0.0000 0.0000 0.0112 0.0221 0.0000 149 150 150 151 151 
leucine -0.2333 0.2992 0.1804 0.1654 -0.3299 0.0042 0.0002 0.0272 0.0424 0.0000 149 150 150 151 151 
lysine 0.0711 0.0558 -0.0307 -0.0502 -0.0282 0.3890 0.4978 0.7093 0.5401 0.7308 149 150 150 151 151 
methionine 0.0566 -0.0702 -0.0140 -0.0851 -0.0308 0.4930 0.3931 0.8648 0.2991 0.7070 149 150 150 151 151 
ornithine 0.0934 -0.0151 -0.0307 -0.2279 0.0391 0.2572 0.8541 0.7096 0.0049 0.6340 149 150 150 151 151 
phenylalanine -0.1576 0.1630 0.1155 0.0721 -0.1532 0.0549 0.0463 0.1595 0.3789 0.0604 149 150 150 151 151 
proline -0.2063 0.1087 0.0916 0.0140 -0.1455 0.0116 0.1855 0.2647 0.8641 0.0746 149 150 150 151 151 
serine 0.2255 -0.1168 -0.0681 -0.4068 0.0839 0.0057 0.1545 0.4079 0.0000 0.3056 149 150 150 151 151 
threonine 0.0248 0.0515 -0.0259 -0.0113 -0.0001 0.7641 0.5315 0.7535 0.8904 0.9991 149 150 150 151 151 
tryptophane -0.0638 0.0487 0.0230 0.0441 -0.0292 0.4395 0.5537 0.7801 0.5907 0.7219 149 150 150 151 151 
tyrosine -0.2963 0.2858 0.1973 0.1289 -0.1939 0.0002 0.0004 0.0155 0.1148 0.0171 149 150 150 151 151 
valine -0.2386 0.3035 0.1408 0.1491 -0.2469 0.0034 0.0002 0.0857 0.0676 0.0022 149 150 150 151 151 
ac-Orn 0.1638 -0.2264 -0.2856 -0.2837 0.2494 0.0459 0.0053 0.0004 0.0004 0.0020 149 150 150 151 151 
ADMA -0.0727 0.0743 0.0483 0.0362 0.0203 0.3782 0.3660 0.5576 0.6590 0.8044 149 150 150 151 151 
alpha AAA -0.3120 0.2754 0.0687 0.1847 -0.2205 0.0001 0.0006 0.4038 0.0232 0.0065 149 150 150 151 151 
creatinine 0.2322 -0.1682 -0.0561 -0.0870 0.2070 0.0044 0.0396 0.4956 0.2883 0.0108 149 150 150 151 151 
kynurenine -0.0561 0.1423 0.0884 0.0528 -0.0017 0.4969 0.0825 0.2821 0.5194 0.9837 149 150 150 151 151 
putrescine 0.1350 -0.0460 0.0246 -0.1074 0.0530 0.1007 0.5762 0.7647 0.1895 0.5178 149 150 150 151 151 
serotonine -0.1244 0.0923 0.0146 0.2384 -0.0274 0.1307 0.2612 0.8597 0.0032 0.7380 149 150 150 151 151 
taurine 0.1144 -0.1572 -0.1017 -0.0837 0.0499 0.1648 0.0547 0.2154 0.3067 0.5427 149 150 150 151 151 
AAAs 
-0.2824 0.1981 0.1572 0.0657 -0.1324 0.0005 0.0151 0.0548 0.4230 0.1051 149 150 150 151 151 
BCAAs 
-0.2840 0.3032 0.1750 0.1441 -0.3078 0.0004 0.0002 0.0322 0.0775 0.0001 149 150 150 151 151 
ISI: insulin sensitivity index, BMI: body mass index, sysBP: systolic blood pressure, TG: triglycerides, HDL: high density lipoprotein cholesterol, ac-Orn: acetylornithine, ADMA: asymmetric dimethylarginine, 
alpha AAA; alpha AAA: alpha-aminoadipic acid, AAAs: the sum of the aromatic amino acids, BCAAs: the sum of the branched-chain amino acids. 
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8. Summary   
8.1. Summary of this thesis 
Type 2 diabetes mellitus (T2D) is a global health burden with an increasing prevalence. 
Prevention of this disease is still insufficient, mainly due to an incomplete understanding of its 
pathophysiology and a lack of suitable tests for early diagnosis. To contribute to the 
understanding of early T2D pathophysiology, this thesis examines the role of physical fitness 
and the hormones leptin and glucagon in women with a recent history of gestational diabetes 
(GDM), a young, high-risk population for T2D. It also looks at plasma amino acids as potential 
early biomarkers for prediabetes and T2D. 
All analyses were conducted in the Prediction, Prevention and Subclassification of type 2 
Diabetes (PPSDiab) study, which prospectively follows women after a pregnancy complicated 
by gestational diabetes and also women after a normoglycemic pregnancy as control subjects. 
The first manuscript of this thesis revealed differences in physical fitness between women 
post GDM and controls. T2D-risk (post GDM-status) was associated with lower physical fitness, 
independent of the BMI. Additionally, physical fitness correlated inversely with fasting plasma 
leptin, independent of the BMI. Therefore, high physical fitness could potentially reduce 
elevated leptin levels or counteract other mechanisms leading to leptin resistance. This may 
alleviate insulin resistance, hyperinsulinemia, and hyperglycemia. 
In a second manuscript, we examined plasma glucagon dynamics in the oral glucose tolerance 
test in three different metabolic groups. Mean glucagon values (fasting and postprandial) 
were higher in the groups at higher risk for T2D, but this was not an ubiquitous finding. An 
unsupervised cluster analysis revealed four clusters of glucagon dynamics that only partially 
overlapped with the metabolic groups. Therefore, we concluded that hyperglucagonemia may 
contribute to hyperglycemia in some individuals, but that it is not a sine qua non for T2D 
development. 
In the third publication of this thesis, we examined whether plasma amino acids can serve as 
biomarkers for pathological glucose tolerance. A systematic literature review and original data 
from the PPSDiab study showed that glutamate, glycine, isoleucine, leucine, proline, and the 
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sum of the branched chain amino acids were associated with pathological glucose tolerance. 
In the PPSDiab study however, only glycine remained significantly associated with glucose 
tolerance after adjustment for BMI. Additionally, besides insulin sensitivity, most amino acids 
also associated with other components of the metabolic syndrome (hypertension, 
dyslipidemia, high BMI, and visceral obesity). Because the metabolic syndrome is already the 
basis for most current T2D risk prediction models, the addition of plasma amino acids does 
not improve prediction. An exception may be glycine, which showed BMI-independent 
associations. 
In sum, this thesis evaluated risk factors and novel biomarker-candidates for T2D in a 
prospective cohort study of young women. It shows novel aspects of the pathophysiology of 
T2D and highlights the heterogeneity of this disease. Personalized approaches to prevention 




8.2. Zusammenfassung dieser Arbeit 
Diabetes mellitus Typ 2 (T2D) stellt ein globales Gesundheitsproblem mit steigender Prävalenz 
dar. Die Prävention der Krankheit ist immer noch unzureichend, vor allem aufgrund des 
unvollständigen Verständnisses ihrer Pathophysiologie und des Mangels an geeigneten Tests 
zur frühen Diagnose. Als Beitrag zur Aufklärung der frühen T2D-Pathophysiologie untersucht 
die vorliegende Dissertation die Rolle von körperlicher Fitness und der Hormone Leptin und 
Glucagon in Frauen nach einer kürzlichen Schwangerschaft mit Gestationsdiabetes (GDM), 
einer jungen hoch-Risiko Population für T2D. Außerdem beschäftigt sie sich mit Plasma-
Aminosäuren als mögliche frühe Biomarker für Prädiabetes und T2D. 
Alle Analysen wurden in der Prädiktion, Prävention und Subklassifikation von Typ 2 Diabetes 
(PPSDiab) Studie durchgeführt, welche prospektiv Frauen nach einer mit Schwangerschaft mit 
Gestationsdiabetes sowie Frauen nach einer normoglykämen Schwangerschaft als Kontrollen 
beobachtet. 
Die erste Auswertung ergab Unterschiede in der körperlichen Fitness zwischen Frauen post 
GDM und Kontrollen. Das T2D-Risiko (post GDM-Status) war BMI-unabhängig mit einer 
geringeren körperlichen Fitness assoziiert. Des Weiteren korrelierte körperliche Fitness BMI-
unabhängig invers mit Nüchtern Plasma-Leptin. Somit könnte eine hohe körperliche Fitness 
möglicherweise erhöhte Leptin-Spiegel reduzieren oder anderen Mechanismen, die zu 
Leptinresistenz führen, entgegenwirken. Das könnte Insulinresistenz, Hyperinsulinämie und 
Hyperglykämie verringern. 
In einer zweiten Analyse wurde in drei verschiedenen metabolischen Gruppen der Verlauf von 
Plasma-Glucagon im oralen Glucosetoleranztest untersucht. Die mittleren Glucagonwerte 
(nüchtern und postprandial) waren höher in Gruppen mit höherem T2D-Risiko, jedoch war 
dieses Ergebnis nicht ubiquitär. Eine unbeaufsichtigte Clusteranalyse ergab vier Cluster von 
Glucagonverläufen, welche nur partiell mit den metabolischen Gruppen überein stimmten. 
Somit kamen wir zu dem Schluss, dass Hyperglucagonämie möglicherweise in manchen 
Individuen zu einer Hyperglykämie beiträgt, dass es aber keine unabdingbare Voraussetzung 
für die Entwicklung von T2D ist. 
In der dritten Publikation dieser Dissertation untersuchten wir, ob Aminosäuren als Biomarker 
für pathologische Glucosetoleranz dienen können. Ein systematischer Literaturreview sowie 
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die Originaldaten aus der PPSDiab-Studie zeigten, dass Glutamat, Glycin, Isoleucin, Leucin, 
Prolin und die Summe der verzweigtkettigen Aminosäuren mit pathologischer 
Glucosetoleranz assoziiert waren. In der PPSDiab Studie blieb nach Adjustieren für BMI jedoch 
lediglich Glycin signifikant mit der Glucosetoleranz assoziiert. Außerdem assoziierten die 
meisten Aminosäuren neben der Insulinsensitivität auch mit anderen Charakteristika des 
Metabolischen Syndroms (Hypertonus, Dyslipidämie, hoher BMI und viszerale Adipositas). Da 
die Charakteristika des Metabolischen Syndroms die Basis für die meisten klassischen T2D-
Risikomodelle bilden, verbessert die Hinzunahme von Aminosäuren die Prädiktion nicht. Eine 
Ausnahme könnte Glycin sein, welches BMI-unabhängige Assoziationen aufwies. 
Zusammengefasst untersuchte diese Dissertation Risikofaktoren und neue Biomarker für T2D 
in einer prospektiven Kohortenstudie junger Frauen. Sie zeigt neue Aspekte der 
Pathophysiologie des T2D auf und hebt die Heterogenität der Erkrankung hervor. Sicherlich 
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